Why the study?
Myocarditis cases have been reported in cancer patients after immune checkpoint therapy, motivating investigation into the cardiotoxic potential of T-cell responses to PD-1/PD-L1 axis blockade in regulating cardiomyocyte injury.
Blockade of PD-1 by nivolumab enhances cardiomyocyte inflammation and apoptosis through the enhancement of T-cell response, providing a mechanistic basis for immune checkpoint inhibitor-associated myocarditis.
No takes yet. Share an insight, caveat, or question.
Highlights inflammatory biomarkers for nivolumab myocarditis risk; hypothesis-generating and requires prospective validation before clinical adoption.
Tay et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: